Discover how simple lifestyle changes — like exercise, diet, and better sleep — can help reduce symptoms and improve quality ...

This variability contributes to delayed diagnosis, with many people enduring symptoms for years before receiving proper treatment. Left untreated, psoriatic arthritis can lead to permanent joint ...

New study shows a subset of psoriatic arthritis patients can achieve long-term remission without DMARDs. Learn who benefits and why it matters for PsA management.

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

In February 2025, A naptysBio announced promising results from a global Phase IIb trial (RENOIR) for rosnilimab, a novel ...

Adults with atopic dermatitis treated with upadacitinib had fewer major adverse cardiovascular events compared with background rates in real-world populations, adding to research supporting the drug’s ...